Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

Journal Articles

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4704.

https://doi.org/10.1182/blood-2024-201052

Published: 2024

Journal Articles

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Blood (2024) 144 (Supplement 1): 4685.1.

https://doi.org/10.1182/blood-2024-208457

Published: 2024

Journal Articles

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 83.

https://doi.org/10.1182/blood-2024-202098

Published: 2024

Journal Articles

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2024-211755

Published: 2024

Journal Articles

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Jacob T Shreve, Michael D Howe, Emmanuel Contreras Guzman, Charalampos Charalampous, Wilson I. Gonsalves, Francis Buadi, Taxiarchis Kourelis, Suzanne R Hayman, Morie A. Gertz, Rafael Fonseca, S. Vincent Rajkumar, Surendra Dasari, Matthew P. Thorpe, Stephen Broski, Shaji Kumar, Moritz Binder

Blood (2024) 144 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2024-202022

Published: 2024

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Iuliana Vaxman, Shaji Kumar, Inbar Cohen, Shai O. Shimony, Angela Dispenzieri, Francis Buadi, David Dingli, Martha Lacy, Eli Muchtar, Prashant Kapoor, William J. Hogan, Suzanne R Hayman, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 7078.

https://doi.org/10.1182/blood-2024-205062

Published: 2024

Journal Articles

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2024-208468

Published: 2024

Journal Articles

A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry

Arwa Bohra, Rafla Hassan, Saurabh Zanwar, Dragan Jevremovic, Horatiu Olteanu, Wilson I. Gonsalves, Gregory Otteson, Pedro Horna, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2024-211626

Published: 2024

Journal Articles

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Blood (2024) 144 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2024-208736

Published: 2024

Journal Articles

Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia

Blood (2024) 144 (Supplement 1): 3315.

https://doi.org/10.1182/blood-2024-200267

Published: 2024

Journal Articles

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Nadine Abdallah, Matthew Rees, Supriya Gupta, Mohammed Elhaj, Radhika Bansal, Terri Menser, Gavin Schaeferle, Joselle Cook, Taxiarchis Kourelis, Rahma M Warsame, Wilson I. Gonsalves, Prashant Kapoor, Francis Buadi, Suzanne R Hayman, David Dingli, Morie A. Gertz, Yi Lin, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2024-211768

Published: 2024

Journal Articles

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Blood (2024) 144 (Supplement 1): 5047.

https://doi.org/10.1182/blood-2024-199229

Published: 2024

Journal Articles

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2024-209102

Published: 2024

Journal Articles

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Saurabh Zanwar, Joseph Novak, Michael D Howe, Moritz Binder, Wilson I. Gonsalves, Esteban Braggio, Vincent Rajkumar, Dragan Jevremovic, Surendra Dasari, Shaji Kumar

Blood (2024) 144 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2024-203350

Published: 2024

Journal Articles

Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Cinnie Soekojo, Susan M. Geyer, Emmanuel Contreras Guzman, Kaitlyn Whitaker, Shaji Kumar, Vincent Rajkumar, Joselle Cook, Yogesh Chawla, Francis Buadi, Angela Dispenzieri, Moritz Binder, Rafael Fonseca, Taro Hitosugi, Dragan Jevremovic, Wilson I. Gonsalves, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 1880.

https://doi.org/10.1182/blood-2024-207440

Published: 2024

Journal Articles

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Arwa Bohra, Surendra Dasari, Wilson I. Gonsalves, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Angela Dispenzieri, Michael M Timm, Dragan Jevremovic, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2024-211902

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2024-210932

Published: 2024

Journal Articles

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Nadia Toumeh, Matthew James Rees, Morie A. Gertz, Angela Dispenzieri, Binoy Yohannan, Suheil Albert Atallah-Yunes, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Suzanne R Hayman, Francis Buadi, David Dingli, Joselle Cook, Rahma M Warsame, Moritz Binder, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar, Eli Muchtar

Blood (2024) 144 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2024-202059

Published: 2024

Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Blood (2024) 144 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2024-208294

Published: 2024

NARROW

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only